MTAP and familial pancreatic carcinoma: It has shown a selective in vitro anti-neoplastic activity against methylthioadenosine phosphorylase (MTAP)-deficient tumours [1,16] such as leukaemias, brain tumours, non-small-cell lung cancers, breast cancers, melanomas, pancreatic cancers, and sarcomas [17-21].